Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Placebo-Controlled, Double-Blind Phase 3 Trial Comparing, Relative to Placebo, the Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer (CATIQ P3)

NCT06861088 is registered in ClinicalTrials.gov with Quercis Pharma AG as lead sponsor.

NCT NCT06861088
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06861088 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Placebo-Controlled, Double-Blind Phase 3 Trial Comparing, Relative to Placebo, the Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer (CATIQ P3)
Lead sponsor
Quercis Pharma AG
Phase
Phase 3
Overall status
Recruiting
Start date
December 19, 2025
Completion date
October 31, 2029
Enrollment
480 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced pancreatic adenocarcinoma, metastatic pancreatic cancer, venous thromboembolism